Showing 6251-6260 of 10732 results for "".
The State of Academic Dermatology
https://practicaldermatology.com/topics/practice-management/the-state-of-academic-dermatology/18843/In this edition of Derm Insider, host Neal Bhatia, MD sits down with Jane Grant-Kels, MD, Sheila Fallon Friedlander, MD, and Kevin Cooper, MD to discuss the challenges and rewards of academic dermatology. From meeting aggressive budgets to dealing with EMRs, academicians face many of the same demandLet's Talk about YouTube and why your Practice should have one
https://practicaldermatology.com/topics/practice-management/let-s-talk-about-youtube-and-why-your-practice-should-have-one/19116/Any form of healthcare, dental and veterinarian practice should have a YouTube account. It is known that people prefer to watch a video to learn and understand something, rather than read an article or look at a picture. YouTube gives your practice the chance to educate your patients or clients.Social Media: Mass Med Society
https://practicaldermatology.com/topics/practice-management/mass-med-society/19360/Massachusetts Medical Society: Social Media Pitfalls and Opportunities, including inadvertent disclosure and security.Medlite - What Physicians are Saying
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/medlite-what-physicians-are-saying/19453/Impressive statements from Doctors using the Medlite laser are given. The benefits and outcomes of specific cases are discussed.The State of AI in Dermatology
https://practicaldermatology.com/issues/january-february-2025/the-state-of-ai-in-dermatology/32927/The term “artificial intelligence” (AI) has been inescapable since OpenAI released ChatGPT to the public in November 2022.Fertility Medications and Chronic Spontaneous Urticaria
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/fertility-medications-and-chronic-spontaneous-urticaria/50955/Michelle Tarbox, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the implications of her International Journal of Dermatology article “Fertility Medications and Urticaria Suptypes: Real-World Comparative Study Analyzing Risks Among Clomiphene, GnRH Agonis“Ask Me Anything” Mentorship Session: Dr. Natasha Mesinkovska on Academia, Alopecia Areata, and More
https://practicaldermatology.com/youngmd-connect/on-demand-virtual-sessions/ask-me-anything-mentorship-session-dr-natasha-mesinkovska-on-academia-alopecia-areata-and-more/48814/Natasha Atanaskova Mesinkovsa, MD, PhD, vice chair for clinical research in the UC Irvine School of Medicine's Department of Dermatology, discusses how she navigated her unique career path, how she balances her various responsibilities now, and more in an "Ask Me Anything" mentorship session.Tips for Success with Fillers
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/tips-for-success-with-fillers/20149/Heidi Waldorf, MD offers tips for getting the best results possible with fillers. From how to evaluate what patients need to considering shapes and proportions, she offers hands-on advice to help achieve optimal outcomes. Plus, she discusses the importance of managing patient expectations.Identifying SCC Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/identifying-scc-risk/20144/Sherrif Ibrahim, MD discusses the challenges of managing squamous cell carcinoma (SCC). Great steps have been made in clinical, pathological staging systems, but Dr. Ibrahim says it’s still difficult to determine what to do with borderline cases. He talks about the need to determine frequency and inDermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approve